|
|
|
| Methylation Status of PCDH8 and TSLC1 Gene Promoters in Ovarian Cancer Tissue and Relationship with Prognosis |
| WANG Rui, LIU Yang, DNEG Yun-jing |
| Department of Obstetrics and Gynecology,Yulin First Hospital,Yulin Shaanxi 719000 |
|
|
|
|
Abstract 【Objective】To investigate the methylation status of the promoter of PCDH8 and TSLC1 genes in ovarian cancer tissue and relationship with prognosis. 【Methods】The clinical data of 104 patients with ovarian cancer who underwent surgical treatment in our hospital from May 2017 to May 2018 were retrospectively analyzed. All patients were followed up for 36 months after surgery. The patients with metastasis,recurrence and death during the follow-up period were set as the poor prognosis group (n=60),and the rest were the good prognosis group (n=44). Methylation-specific polymerase chain reaction (MSP) was used to detect the methylation status of PCDH8 and TSLC1 gene promoters in ovarian cancer tissues of all patients. Univariate analysis and multivariate analysis were used to analyze the factors affecting the poor prognosis of ovarian cancer patients.【Results】The methylation rates of PCDH8 gene promoter and TSLC1 gene promoter in ovarian cancer tissue of patients with poor prognosis were 80.00% (48/60) and 58.33% (35/60),respectively,which were significantly higher than those of patients with good prognosis 36.36% (16/44) and 18.18% (8/44),respectively. The difference was statistically significant(χ2=20.422、16.875,P<0.05). There were statistically significant differences in FIGO stage,lymph node metastasis,degree of differentiation,PCDH8 gene promoter methylation status,and TSLC1 gene promoter methylation status between the poor prognosis group and the good prognosis group (P<0.05). FIGO stage Ⅲ~Ⅳ,lymph node metastasis,degree of differentiation G3,positive PCDH8 and TSLC1 gene promoter methylation status were all risk factors for the poor prognosis of ovarian cancer patients (P<0.05).【Conclusion】The positive rates of both PCDH8 and TSLC1 gene promoter methylation in the cancer tissue of patients with poor prognosis are significantly higher than those of patients with good prognosis. The methylation status of both PCDH8 and TSLC1 gene promoters is significantly correlated with the prognosis and can be used to evaluate the prognosis of patients with ovarian cancer.
|
|
Received: 09 March 2022
|
|
|
|
|
|
[1] 葛倩倩.多西他赛联合异环磷酰胺对卵巢癌 CAOV3 细胞 cyclinD1 及GADD153表达的影响[J].医学临床研究,2019,36(10):1893-1895.
[2] ZHANG P,WANG H,WANG J,et al. Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer[J].Oncol Lett ,2017,14(2):1657-1664.
[3] 陈现亮,吴义娟.MTA1和TSLC1表达与结肠腺瘤癌变相关性研究[J].中华肿瘤防治杂志,2017,24(13):871-874.
[4] 林仲秋,谢玲玲,李晶. FIGO 2013卵巢癌、输卵管癌、腹膜癌新分期解读[J].中国实用妇科与产科杂志,2013,29(12):921-923.
[5] 李巍,崔恒,冯捷,等. 卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498.
[6] 薛凤霞,赵敬. 复发性卵巢癌的诊断[J].中国实用妇科与产科杂志,2005,21(7):385-386.
[7] LARSEN L K,LIND G E,GULDBERG P,et al. DNA-methylation-based detection of urological cancer in urine:overview of biomarkers and considerations on biomarker design,source of DNA,and detection technologies[J].Int J Mol Sci,2019,20(11):2657.
[8] 张丹杰,李少民,姜建涛,等. 胃癌中PCDH8基因启动子甲基化状态及其临床意义[J].现代肿瘤医学,2018,26(15):2417-2421.
[9] 陈素云,赵志新,褚邦勇. 肝癌癌组织PCDH8、RIZ1基因甲基化状态及临床意义[J].重庆医学,2020,49(24):4075-4079.
[10] YANSHI L,CHUAN L,ZHIHAI W,et al. Expression of protocadherin8:Function as a tumor suppressor in hypopharyngeal carcinoma [J].Cancer Biomark,2018,22(3):495-502.
[11] 冶正财,安钰,李宏亮,等. 食管鳞癌组织中TSLC1基因启动子甲基化状态检测的临床意义[J].现代肿瘤医学,2018,26(15):2368-2370.
[12] 吴晓,庄轶轩,陈炯玉,等. 肺癌肿瘤抑制因子1在雌激素受体、孕激素受体不同表达乳腺癌患者中的临床意义[J].转化医学杂志,2017,6(5):261-265.
[13] 王碧荣,袁高乐,梁启廉,等. 肺癌肿瘤抑制物1对人大肠癌细胞株HT29增殖与凋亡的影响[J].中华实验外科杂志,2018,35(2):234-237.
[14] 刘玉红,高菊荣,王琰. 口腔鳞状细胞癌中TSLC1基因启动子甲基化状态检测的临床意义[J].现代肿瘤医学,2017,25(21):3423-3425. |
|
|
|
2023, Vol. 40 
